Urgent Field Safety Notice from ResMed regarding Astral 100/150 ventilators

03 July 2026

Please see below linked documents of the Urgent Field Safety Notice from ResMed regarding certain Astral 100 and Astral 150 ventilators manufactured prior to October 2024.

ResMed has identified a rare issue whereby an internal electrical component may fail and cause the ventilator to enter a fail-safe state, resulting in therapy stopping and requiring immediate alternative ventilation. The reported occurrence rate is approximately 0.1%, with five adverse events reported globally, one of which was classified as serious.

Key points:

Patients should not discontinue therapy unless advised to do so by their treating clinician and an appropriate alternative means of ventilation is available.
Services should ensure that ventilator-dependent patients have appropriate monitoring, trained carers and access to functional backup ventilation equipment where required. Patients and carers should be familiar with the actions to take in the event of an alarm or device failure.
ResMed is implementing a phased inspection and correction programme, prioritising patients at highest clinical risk, recognising that immediate correction of all affected devices is not possible due to component constraints.
Services should review affected patients and apply clinical judgement when assessing risk and prioritising inspection activities.
There is currently a significant constraint on replacement components and new Astral device availability, and services may need to consider alternative ventilator options for new patients.

Please review the linked the full field safety notice, physician letter and product availability update documentation and follow your local processes for identifying affected devices and assessing patient risk.

Posted by the ARTP Manufacturer's Liaison Committee

View other News